Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (28)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Camilleri-Broët, S.
Right arrow Articles by Pujade-Lauraine, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Camilleri-Broët, S.
Right arrow Articles by Pujade-Lauraine, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:104-112, 2004
© 2004 European Society for Medical Oncology

Original Paper

HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group

Received 20 February 2003; revised 5 September 2003; accepted 10 September 2003

Background:

Despite numerous studies, no biological marker has been identified that accurately predicts prognosis of advanced ovarian cancer. Tumors from a homogeneous population of 117 patients with a stage III/IV ovarian cancer, enrolled in a multicenter prospective GINECO clinical trial were analyzed retrospectively.

Patients and methods:

All patients received the same platinum-based combination therapy and were followed-up for a median of 68 months. Tumor expression of Ki67, BCL-2, BAX, P53 or c-erbB-2 proteins was evaluated immunohistochemically on paraffin-embedded tissues and their prognostic impact analyzed.

Results:

The median rate of Ki67-positive nuclear area was 30%. BCL-2, BAX and P53 proteins were expressed in 52, 54 and 71% of the tumors, respectively, while HER-2 protein was overexpressed in 16%. Only HER-2 overexpression was significantly associated with shorter progression-free survival and overall survival. According to our multivariate analysis, the HER-2 prognostic impact was independent of classical clinical prognostic factors.

Conclusion:

HER-2 appeared to influence the outcome of advanced ovarian cancer patients included in a clinical trial with prolonged follow-up, thereby suggesting that HER-2 is a potential target for treatment of this cancer.

S. Camilleri-Broët1,*, A. C. Hardy-Bessard2, A. Le Tourneau1, D. Paraiso2, O. Levrel1, B. Leduc3, S. Bain1, H. Orfeuvre4, J. Audouin1 and E. Pujade-Lauraine2

1 Service d’Anatomie Pathologique and 2 Service d’Oncologie, Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, UFR Paris VI, Paris; 3 Radiothérapie Oncologie, Centre Hospitalier Brive La Gaillarde; 4 Service d’Onco-hématologie, Hôpital Fleyriat, Bourg en Bresse, France

Key words: HER-2, ovarian cancer, prognosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Chem.Home page
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clin. Chem., December 1, 2008; 54(12): e11 - e79.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
A. A. Garcia
Small Molecules: Big Changes in the Cancer Treatment Paradigm
Journal of Pharmacy Practice, February 1, 2008; 21(1): 17 - 35.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
J. K. Chan, C. A. Hamilton, M. K. Cheung, M. Karimi, J. Baker, J. M. Gall, S. Schulz, S. H. Thorne, N. N. Teng, C. H. Contag, et al.
Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
Clin. Cancer Res., March 15, 2006; 12(6): 1859 - 1867.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Goodell, L. G. Salazar, N. Urban, C. W. Drescher, H. Gray, R. E. Swensen, M. W. McIntosh, and M. L. Disis
Antibody Immunity to the p53 Oncogenic Protein Is a Prognostic Indicator in Ovarian Cancer
J. Clin. Oncol., February 10, 2006; 24(5): 762 - 768.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. J. Gilbertson
ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty
Oncologist, August 1, 2005; 10(7): 508 - 517.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.